TREKSTOR
28.1.2021 11:45:02 CET | Business Wire | Press release
Today the TREKSTOR GmbH, the manufacturer behind the blnk branded healthcare products, completed delivery of 100.000 FFP2 class respirators to the Tafel Deutschland. This is a reaction to the increased demand for certified PPE products created by both decisions of the federal government as well as the FFP2 mandate active in the state of Bavaria.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005522/en/
„As a German company, which mainly exists today due to the sales of entry-level PCs and tablets to price-sensitive customers in the past, we are aware of our responsibility to our fellow citizens“ , Shimon Szmigiel, CEO of TREKSTOR, explains. „Many of them are lagging the financial prowess to purchase high quality protective equipment, a state that is worsened by lay-offs and short-time work arrangements.”
Therefore, TREKSTOR decided on short notice to donate 50.000 packs containing 2 pcs of its own blnk brand model BL-03N FFP2 respirators, which are normally sold to government, hospital and care facilities. As do all FFP2 respirators, it filters ≥94% of particles, in the COVID-19 relevant comparison with NaCL, the masks even performed above the 99% mark.
„The selection of Tafel Deutschland as our partner was very easy“ , adds Shimon Szmigiel. This is due to existing infrastructure and experience when it comes to distributing food, which makes the Tafel to a unique distribution network. Based on the agreement, the respirators were delivery to a central warehouse in Nurnberg and will from there be distributed to the 168 locations in Bavaria according to demand.
Jochen Brühl, Chairman of Tafel Deutschland: „We are delighted for this wonderful support. People in poverty are especially affected by this crisis. As important as the mask mandate is, it is a financial burden for poor people. Around 1.6 million people rely on our food banks, among them 430.000 retirees and up to 500.000 children and youths. The donation by TREKSTOR helps them to protect themselves while also relieving some of the financial pressure. For that, we are very thankful.“
TREKSTOR is aware, that this donation is literally only a drop in the ocean, which is why Shimon Szmigiel appeals to all other businesses: “If you are active in the same areas we are – or if you are not, take heart, temporarily forget about profit, and do something good.”
About TREKSTOR / blnk Healthcare
TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies, and end-consumers.
About Tafel Deutschland e.V.
The 950 charitable food banks in Germany collect impeccable surplus food from retailers and manufacturers and distribute it regularly to more than 1.6 million poor people across the country. In doing so, they create a balance between waste and poverty. With around 60,000 volunteers who are involved in the food banks, the food banks are one of the largest socio-ecological movements in Germany. The food banks are organized in the umbrella organization Tafel Deutschland e. V.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005522/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
